Geneius Biotechnology's Debt - III Round

Geneius Biotechnology raised a round of funding on June 23, 2017.

Geneius is developing a series of cancer products utilizing a proprietary Cyto-toxic T Lymphocyte (CTL) platform which rebalances the immune system to actively reject and reinstate protective immuno-s…

Articles about Geneius Biotechnology's Debt - III Round: